2000
Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up
Vassilikos E, Yu H, Trachtenberg J, Nam R, Narod S, Bromberg I, Diamandis E. Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up. Clinical Biochemistry 2000, 33: 115-123. PMID: 10751589, DOI: 10.1016/s0009-9120(99)00099-5.Peer-Reviewed Original ResearchMeSH KeywordsAgedDisease-Free SurvivalFluorescent Antibody TechniqueFollow-Up StudiesHumansMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRecurrenceRegression AnalysisReproducibility of ResultsSensitivity and SpecificityTime FactorsTreatment OutcomeConceptsProstate cancer patientsRadical prostatectomySerum PSACancer patientsPSA assaysUltrasensitive prostate specific antigenPre-operative PSAGroup of patientsSerial serum samplesEarly therapeutic interventionSeminal vesicle invasionSurgical margin positivityProstate-specific antigenRegular PSAUltrasensitive PSAPSA increaseMargin positivityClinical stageGleason scorePrognostic indicatorCapsular invasionTissue involvementTumor volumePatientsFast relapse
1996
Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer
Yu H, Levesque M, Khosravi M, Papanastasiou-Diamandi A, Clark G, Diamandis E. Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. British Journal Of Cancer 1996, 74: 1242-1247. PMID: 8883411, PMCID: PMC2075943, DOI: 10.1038/bjc.1996.523.Peer-Reviewed Original ResearchConceptsInsulin-like growth factorProstate-specific antigenIGFBP-3IGF-IIBreast cancerS-phase fractionIGFBP-1Prognostic indicatorGrowth factorActive insulin-like growth factorsHER-2/neu proteinUnfavourable prognostic indicatorPrimary breast cancerEpidermal growth factor receptorSteroid hormone receptorsTumor tissue cytosolGrowth factor receptorIGF functionEstrogen receptorDNA ploidyPossible associationNeu proteinCancerTissue cytosolsHormone receptorsCreatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients
Zarghami N, Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Sismondi P, Diamandis E. Creatine kinase BB isoenzyme levels in tumour cytosols and survival of breast cancer patients. British Journal Of Cancer 1996, 73: 386-390. PMID: 8562347, PMCID: PMC2074443, DOI: 10.1038/bjc.1996.66.Peer-Reviewed Original ResearchConceptsCK-BB levelsCK-BBTumor cytosolsEstrogen receptor-negative cancersEstrogen receptor-positive tumorsReceptor-positive tumorsBreast cancer patientsRisk of deathReceptor-negative cancersRisk of relapseBreast tumor cytosolsHistological typeClinicopathological variablesPatient survivalPrognostic indicatorTumor stageAggressive tumorsCancer patientsProgesterone receptorUnivariate analysisHigh riskBB groupIsoenzyme levelsPatientsBreast tumors
1995
Prostate-specific antigen in serum of women with breast cancer
Giai M, Yu H, Roagna R, Ponzone R, Katsaros D, Levesque M, Diamandis E. Prostate-specific antigen in serum of women with breast cancer. British Journal Of Cancer 1995, 72: 728-731. PMID: 7545417, PMCID: PMC2033864, DOI: 10.1038/bjc.1995.401.Peer-Reviewed Original ResearchConceptsSerum prostate-specific antigenProstate-specific antigenBreast cancer patientsBreast cancerPSA levelsCancer patientsTumor cytosolsBreast tumorsPSA concentrationFree prostate-specific antigenSerum of womenFavorable prognostic indicatorSerum PSA levelsNormal male serumFemale breast tumorsBreast cancer diagnosisPresurgical seraPrognostic indicatorSurgical removalNormal breastMale serumCancerSerumCancer diagnosisTumorsImmunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators
Levesque M, Clark G, Yu H, Diamandis E. Immunofluorometric analysis of p53 protein and prostate-specific antigen in breast tumours and their association with other prognostic indicators. British Journal Of Cancer 1995, 72: 720-727. PMID: 7545416, PMCID: PMC2033897, DOI: 10.1038/bjc.1995.400.Peer-Reviewed Original ResearchConceptsS-phase fractionEpidermal growth factor receptorHER-2/neuProgesterone receptorPrognostic indicatorBreast cancerBreast tumorsProstate-specific antigen expressionIndependent prognostic indicatorP53 proteinProstate-specific antigenAggressive tumor phenotypeWilcoxon rank sum analysisBreast tumor extractsStatus of p53Growth factor receptorPresence of PSARank-sum analysisFavorable prognosisPrognostic factorsBetter prognosisLevels of ERPresence of p53Antigen expressionTumor extractsImmunoreactive prostate‐specific antigen in lung tumors
Levesque M, Yu H, D'Costa M, Tadross L, Diamandis E. Immunoreactive prostate‐specific antigen in lung tumors. Journal Of Clinical Laboratory Analysis 1995, 9: 375-379. PMID: 8587005, DOI: 10.1002/jcla.1860090607.Peer-Reviewed Original ResearchConceptsProstate-specific antigenImmunoreactive prostate-specific antigenLung tumor extractsFavorable prognostic indicatorSquamous cell carcinomaSteroid hormone actionMale patientsPrognostic significanceCell carcinomaPrognostic indicatorLung cancerLung tissueBreast cancerLung tumorsPresence of PSAProstate carcinomaTumor extractsBreast tumorsBiochemical markersHormone actionTumorsEpithelial cellsCarcinomaCancerAntigen
1994
Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer
Levesque M, Diamandis E, Yu H, Sutherland D. Quantitative analysis of mutant p53 protein in breast tumor cytosols and study of its association with other biochemical prognostic indicators in breast cancer. Breast Cancer Research And Treatment 1994, 30: 179-195. PMID: 7524772, DOI: 10.1007/bf00666062.Peer-Reviewed Original ResearchConceptsCarcinoembryonic antigenPrognostic indicatorBreast cancerBreast tumorsBiochemical prognostic indicatorsCandidate prognostic indicatorBreast tumor cytosolsSteroid hormone receptorsNegative associationProgesterone receptorTumor cytosolsMutant p53 proteinTumor extractsP53 tumor suppressor gene productSpecific antigenBiochemical parametersObserved associationsHormone receptorsImmunofluorometric procedureStrong positive associationCognate steroid ligandP53 proteinReceptorsStrong negative associationTumor suppressor gene productEctopic production of prostate specific antigen by a breast tumor metastatic to the ovary
Yu H, Diamandis E, Levesque M, Sismondi P, Zola P, Katsaros D. Ectopic production of prostate specific antigen by a breast tumor metastatic to the ovary. Journal Of Clinical Laboratory Analysis 1994, 8: 251-253. PMID: 7523638, DOI: 10.1002/jcla.1860080412.Peer-Reviewed Original ResearchConceptsProstate-specific antigenMetastatic ovarian cancerPrimary breast tumorsBreast tumorsOvarian cancerSpecific antigenPrimary ovarian cancer tumorsFavorable prognostic indicatorOvarian cancer tumorsMetastatic sitesTumor metastaticPrognostic indicatorBreast cancerPSA productionEctopic productionTumorsSteroid hormonesCancer tumorsCancerPatientsAntigenTreatmentLow levelsHigh levelsMetastatic